EA032000B1 - Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой - Google Patents
Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой Download PDFInfo
- Publication number
- EA032000B1 EA032000B1 EA201400966A EA201400966A EA032000B1 EA 032000 B1 EA032000 B1 EA 032000B1 EA 201400966 A EA201400966 A EA 201400966A EA 201400966 A EA201400966 A EA 201400966A EA 032000 B1 EA032000 B1 EA 032000B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ivig
- cells
- patient
- nerve
- body weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605117P | 2012-02-29 | 2012-02-29 | |
| PCT/US2013/028350 WO2013130826A2 (en) | 2012-02-29 | 2013-02-28 | Igg stimulated remyelination of peripheral nerves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201400966A1 EA201400966A1 (ru) | 2014-12-30 |
| EA032000B1 true EA032000B1 (ru) | 2019-03-29 |
Family
ID=47884569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400966A EA032000B1 (ru) | 2012-02-29 | 2013-02-28 | Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой |
| EA201892521A EA201892521A1 (ru) | 2012-02-29 | 2013-02-28 | РЕМИЕЛИНИЗАЦИЯ ПЕРИФЕРИЧЕСКИХ НЕРВОВ, СТИМУЛИРОВАННАЯ IgG |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892521A EA201892521A1 (ru) | 2012-02-29 | 2013-02-28 | РЕМИЕЛИНИЗАЦИЯ ПЕРИФЕРИЧЕСКИХ НЕРВОВ, СТИМУЛИРОВАННАЯ IgG |
Country Status (21)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3590960T3 (fi) * | 2012-02-29 | 2023-04-25 | Takeda Pharmaceuticals Co | Perifeeristen hermojen IgG-stimuloitu remyelinaatio |
| US9690975B2 (en) * | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11511136B2 (en) | 2017-11-17 | 2022-11-29 | The Research Foundation For The State University Of New York | Method for treating damaged peripheral nerves using x-ray microbeam irradiation |
| EP3908256A4 (en) * | 2019-01-07 | 2022-09-21 | Mallinckrodt Ard IP Unlimited Company | METHOD TO PROMOTE REMYELINATION |
| GB201907882D0 (en) | 2019-06-03 | 2019-07-17 | Cyprus Foundation For Muscular Dystrophy Res | Methods |
| EP4737584A1 (en) * | 2023-06-30 | 2026-05-06 | FUJIFILM Corporation | Method for evaluating intercellular interaction of neuroinflammation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (cg-RX-API-DMAC10.html) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| AT376367B (de) | 1983-03-16 | 1984-11-12 | Immuno Ag | Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten |
| DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| ATE36457T1 (de) | 1983-05-02 | 1988-09-15 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern. |
| AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| AT390560B (de) | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| WO1992003536A1 (en) * | 1990-08-15 | 1992-03-05 | University Of Miami And Its School Of Medicine | Autotransplantation of schwann cells to promote nervous system repair |
| AT402891B (de) | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| EP0674531A1 (de) | 1992-12-16 | 1995-10-04 | IMMUNO Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| HRP940645A2 (en) | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| TW491855B (en) | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| ID27417A (id) | 1998-06-09 | 2001-04-05 | Statens Seruminstitut | Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya |
| SE0001128D0 (sv) | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
| EP2287190B1 (en) * | 2000-05-10 | 2014-12-17 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| JP2003070465A (ja) * | 2001-08-31 | 2003-03-11 | Keio Gijuku | シュワン細胞の培養方法 |
| JP2007521249A (ja) | 2003-01-24 | 2007-08-02 | エラン ファーマシューティカルズ，インコーポレイテッド | 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療 |
| US20070244305A1 (en) | 2004-01-30 | 2007-10-18 | Suomen Punainen Risti Veripalvelu | Process for The Manufacture of Virus Safe Immunoglobulin |
| CA2557229C (en) | 2004-02-27 | 2012-07-10 | Octapharma Ag | A method of providing a purified, virus safe antibody preparation |
| EA017403B1 (ru) * | 2007-02-02 | 2012-12-28 | Байоджен Айдек Эмэй Инк. | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов |
| US7854703B2 (en) | 2007-09-25 | 2010-12-21 | Intel Corporation | Peripheral neuropathy detection |
| CA2643496C (en) | 2008-11-06 | 2015-02-03 | Michael Fehlings | The therapeutic use of igg as a neuroprotective agent |
| CN102021140B (zh) * | 2009-09-18 | 2013-04-24 | 上海市第一人民医院 | 一种分离、纯化许旺细胞的方法 |
| FI3590960T3 (fi) * | 2012-02-29 | 2023-04-25 | Takeda Pharmaceuticals Co | Perifeeristen hermojen IgG-stimuloitu remyelinaatio |
-
2013
- 2013-02-28 FI FIEP19180237.0T patent/FI3590960T3/fi active
- 2013-02-28 ES ES19180237T patent/ES2943585T3/es active Active
- 2013-02-28 BR BR112014021240A patent/BR112014021240A2/pt not_active Application Discontinuation
- 2013-02-28 KR KR1020227011045A patent/KR102673154B1/ko active Active
- 2013-02-28 PT PT137096756T patent/PT2820042T/pt unknown
- 2013-02-28 CN CN201380021280.8A patent/CN104302666A/zh active Pending
- 2013-02-28 EA EA201400966A patent/EA032000B1/ru not_active IP Right Cessation
- 2013-02-28 DK DK13709675T patent/DK2820042T3/da active
- 2013-02-28 MX MX2014010387A patent/MX369444B/es active IP Right Grant
- 2013-02-28 WO PCT/US2013/028350 patent/WO2013130826A2/en not_active Ceased
- 2013-02-28 CN CN201910611688.XA patent/CN110343171A/zh active Pending
- 2013-02-28 CN CN201910008205.7A patent/CN109966488A/zh active Pending
- 2013-02-28 EA EA201892521A patent/EA201892521A1/ru unknown
- 2013-02-28 NZ NZ629867A patent/NZ629867A/en unknown
- 2013-02-28 KR KR1020147027130A patent/KR102170615B1/ko active Active
- 2013-02-28 JP JP2014560045A patent/JP6335800B2/ja active Active
- 2013-02-28 AU AU2013203088A patent/AU2013203088B2/en active Active
- 2013-02-28 IL IL277103A patent/IL277103B2/en unknown
- 2013-02-28 DK DK19180237.0T patent/DK3590960T3/da active
- 2013-02-28 IL IL274512A patent/IL274512B2/en unknown
- 2013-02-28 SG SG11201405302WA patent/SG11201405302WA/en unknown
- 2013-02-28 CN CN201710896364.6A patent/CN107551269A/zh active Pending
- 2013-02-28 KR KR1020207030277A patent/KR20200126005A/ko not_active Ceased
- 2013-02-28 PL PL13709675T patent/PL2820042T3/pl unknown
- 2013-02-28 PL PL19180237.0T patent/PL3590960T3/pl unknown
- 2013-02-28 EP EP19180237.0A patent/EP3590960B1/en active Active
- 2013-02-28 US US13/781,283 patent/US8986670B2/en active Active
- 2013-02-28 ES ES13709675T patent/ES2755056T3/es active Active
- 2013-02-28 PT PT191802370T patent/PT3590960T/pt unknown
- 2013-02-28 EP EP13709675.6A patent/EP2820042B1/en active Active
- 2013-03-01 TW TW106122004A patent/TWI700297B/zh active
- 2013-03-01 TW TW107124197A patent/TW201838654A/zh unknown
- 2013-03-01 AR ARP130100662A patent/AR090211A1/es not_active Application Discontinuation
- 2013-03-01 TW TW102107471A patent/TWI632158B/zh active
-
2014
- 2014-08-26 IL IL234303A patent/IL234303B/en active IP Right Grant
- 2014-08-28 MX MX2019012496A patent/MX2019012496A/es unknown
-
2015
- 2015-02-18 US US14/625,542 patent/US9834593B2/en active Active
-
2016
- 2016-02-23 AU AU2016201137A patent/AU2016201137B2/en active Active
-
2017
- 2017-09-13 JP JP2017175330A patent/JP6637934B2/ja active Active
- 2017-10-30 US US15/798,313 patent/US10494418B2/en active Active
-
2018
- 2018-01-02 AU AU2018200026A patent/AU2018200026B2/en active Active
- 2018-06-25 HK HK18108139.5A patent/HK1248534A1/zh unknown
-
2019
- 2019-10-04 JP JP2019183415A patent/JP6979990B2/ja active Active
- 2019-10-18 US US16/657,920 patent/US20200216518A1/en not_active Abandoned
- 2019-11-28 AR ARP190103486A patent/AR117207A2/es unknown
-
2021
- 2021-06-14 US US17/347,380 patent/US20210300997A1/en not_active Abandoned
Non-Patent Citations (17)
| Title |
|---|
| COLOVER, J.: "Polyneuropathy in type 2 diabetes mellitus", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 358, no. 9298, 15 December 2001 (2001-12-15), AMSTERDAM, NL, pages 2086, XP004805732, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(01)07124-0 * |
| ENGLAND, J.D. ASBURY, A.K.: "Peripheral neuropathy", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 363, no. 9427, 26 June 2004 (2004-06-26), AMSTERDAM, NL, pages 2151 - 2161, XP004778376, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(04)16508-2 * |
| HONMOU O, ET AL.: "RESTORATION OF NORMAL CONDUCTION PROPERTIES IN DEMYELINATED SPINAL CORD AXONS IN THE ADULT RAT BY TRANSPLANTATION OF EXOGENOUS SCHWANNCELLS", THE JOURNAL OF NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, US, vol. 16, no. 10, 15 May 1996 (1996-05-15), US, pages 3199 - 3208, XP002945997, ISSN: 0270-6474 * |
| JOERG-PATRICK STÜBGEN;: "Drug-induced dysimmune demyelinating neuropathies", JOURNAL OF NEUROLOGICAL SCIENCES., ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM., NL, vol. 307, no. 1, 11 May 2011 (2011-05-11), NL, pages 1 - 8, XP028234970, ISSN: 0022-510X, DOI: 10.1016/j.jns.2011.05.010 * |
| KRENDEL DAVID A; COSTIGAN DONAL A; HOPKINS LINTON C: "Successful treatment of neuropathies in patients with diabetes mellitus", ARCHIVES OF NEUROLOGY., AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 52, no. 11, 1 November 1995 (1995-11-01), US, pages 1053 - 1061, XP008161377, ISSN: 0003-9942, DOI: 10.1001/archneur.1995.00540350039015 * |
| KUHLMANN T, WENDLING U, NOLTE C, ZIPP F, MARUSCHAK B, STADELMANN C, SIEBERT H, BRÜCK W.: "Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins", JOURNAL OF NEUROSCIENCE RESEARCH., WILEY-LISS., US, vol. 67, no. 2, 15 January 2002 (2002-01-15), US, pages 185 - 190, XP002706323, ISSN: 0360-4012, DOI: 10.1002/jnr.10104 * |
| N. LATOV , JOHN H. J. WOKKE , JOHN J. KELLY , BYRON WAKSMAN: "Immunological and infectious diseases of the peripheral nerves", 28 May 1998, CAMBRIDGE UNIV. PRESS, Cambridge, ISBN: 978-0-521-46265-5, article "Immunology and infectious diseases of the peripheral nerves , passage", pages: 340 - 340, XP002706321 * |
| NOTGHI, L.M. ; WRIGHT, S. ; QUINLIVAN, R.: "P12-12 Neonatal axonal neuropathy: a curious presentation of congenital hypomyelination", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE,, IE, vol. 121, 1 October 2010 (2010-10-01), IE, pages S174 - S175, XP027454865, ISSN: 1388-2457, DOI: 10.1016/S1388-2457(10)60716-X * |
| ODAKA M, ET AL: "Treatment response to steroid and intravenous immunoglobulin in a patient with chronic sensory demyelinating neuropathy", JOURNAL OF CLINICAL NEUROMUSCULAR DISEASE, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 8, no. 4, 1 June 2007 (2007-06-01), US, pages 207 - 211, XP002695284, ISSN: 1522-0443, DOI: 10.1097/CND.0b013e318070bfeb * |
| SEKIGUCHI, K. ; KANDA, F. ; TODA, T. ; KOHARA, N.: "P12-11 Nerve conduction characteristics of infliximab induced demyelinating neuropathy", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE,, IE, vol. 121, 1 October 2010 (2010-10-01), IE, pages S174, XP027454864, ISSN: 1388-2457, DOI: 10.1016/S1388-2457(10)60715-8 * |
| STANGEL M: "[Transplantation of myelinating cells as regenerative therapy for multiple sclerosis: Experimental basis and present state of clinical studies.]", NERVENARZT., SPRINGER VERLAG, BERLIN., DE, vol. 73, no. 10, 1 October 2002 (2002-10-01), DE, pages 937 - 945, XP002706322, ISSN: 0028-2804, DOI: 10.1007/s00115-002-1370-8 * |
| VAN SCHAIK I N; VERMEULEN M; BRAND A: "Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?", MULTIPLE SCLEROSIS JOURNAL (MSJ), SAGE PUBLICATIONS, BASINGSTOKE, GB, vol. 3, no. 2, 1 April 1997 (1997-04-01), BASINGSTOKE, GB, pages 98 - 104, XP008161364, ISSN: 1352-4585, DOI: 10.1177/135245859700300208 * |
| VARGAS M E, WATANABE J, SINGH S J, ROBINSON W H, BARRES B A: "Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 107, no. 26, 29 June 2010 (2010-06-29), US, pages 11993 - 11998, XP002695282, ISSN: 0027-8424, DOI: 10.1073/pnas.1001948107 * |
| VERMA A; BRADLEY W G: "High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy.", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 44, no. 2, 1 February 1994 (1994-02-01), US, pages 248 - 250, XP008163795, ISSN: 0028-3878, DOI: 10.1212/WNL.44.2.248 * |
| WARRINGTON A E, ET AL.: "HUMAN MONOCLONAL ANTIBODIES REACTIVE TO OLIGODENDROCYTES PROMOTE REMYELINATION IN A MODEL OF MULTIPLE SCLEROSIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 97, no. 12, 6 June 2000 (2000-06-06), US, pages 6820 - 6825, XP000941806, ISSN: 0027-8424, DOI: 10.1073/pnas.97.12.6820 * |
| ZHANG, J. ; O'CARROLL, S.J. ; WU, A. ; NICHOLSON, L.F.B. ; GREEN, C.R.: "A model for ex vivo spinal cord segment culture-A tool for analysis of injury repair strategies", JOURNAL OF NEUROSCIENCE METHODS., ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM., NL, vol. 192, no. 1, 30 September 2010 (2010-09-30), NL, pages 49 - 57, XP027258913, ISSN: 0165-0270 * |
| ZOCHODNE DW, ISAAC D, JONES C.: "Failure of immunotherapy to prevent, arrest or reverse diabetic lumbosacral plexopathy", ACTA NEUROLOGICA SCANDINAVICA., MUNKSGAARD, COPENHAGEN., DK, vol. 107, no. 4, 1 April 2003 (2003-04-01), DK, pages 299 - 301, XP002695283, ISSN: 0001-6314, DOI: 10.1034/j.1600-0404.2003.02107.x * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6979990B2 (ja) | 末梢神経のＩｇＧ刺激性再ミエリン化法 | |
| HK40018190B (en) | Igg stimulated remyelination of peripheral nerves | |
| EA040995B1 (ru) | Ремиелинизация периферических нервов, стимулированная igg | |
| HK40018190A (en) | Igg stimulated remyelination of peripheral nerves | |
| RU2844863C1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта | |
| Sonoda et al. | Neutrophil‐dominant experimental autoimmune uveitis in CC‐chemokine receptor 2 knockout mice | |
| JP7748728B2 (ja) | 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用 | |
| HK1206035B (en) | Igg stimulated remyelination of peripheral nerves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ KG TJ TM |
|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM |